Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal

A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan